Igor Korolev, DO, PhD 🧠
Greater Boston
108K followers
500+ connections
View mutual connections with Igor
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Igor
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Services
View Igor’s full profile
Other similar profiles
-
Xiong Liu
Cambridge, MAConnect -
Eric Fiolkoski
Arvada, COConnect -
Sajjad Raza, MD, PhD
New Brunswick, NJConnect -
Richard S. Yoon, MD
Jersey City, NJConnect -
Debarshi Datta, PhD
Boca Raton, FLConnect -
Allison Squires
Global Health Services & Workforce Researcher specializing in nurses & midwives. Domestic research interests centered on improving immigrant health outcomes.
New York, NYConnect -
Ritesh Mohan Srivastava
GurugramConnect -
Sorena Nadaf-Rahrov, MS, MMI, PhDc
Advancing Precision Oncology | Applying RWE & Data Science | Innovating Digital Health Solutions | Transforming Clinical & Translational Research | Expanding AI Integration Across Health Systems
Los Angeles Metropolitan AreaConnect -
Steve Byun
Ellicott City, MDConnect -
Jimit Doshi
Philadelphia, PAConnect -
Lingling Shen
Greater BostonConnect -
Hants Williams, PhD, RN, PHN
New York, NYConnect -
Jennifer McCafferty-Fernandez, PhD, FACHE
Managing Partner, Critical Path Advisors, LLC
Miami, FLConnect -
Matt Charnetski
Director, Simulation Based Education and Research & Interprofessional Continuing Education (SBERI) at Dartmouth Health
West Lebanon, NHConnect -
Eric J. Daza, DrPH, MPS
United StatesConnect -
Ina Goldberg
New York, NYConnect -
Xiaochuan 'David' Liu
New York City Metropolitan AreaConnect -
Peter Pavlidakey
Professor, Director of Dermatopathology and Dermatopathology Fellowship at University of Alabama at Birmingham
Birmingham, ALConnect -
Nazanin Hazhir Karzar
Internal Medicine Resident
Las Vegas, NVConnect
Explore more posts
-
General Psychiatry
New research shows that connectome-based predictive modeling can track cravings during long-term opioid abstinence, uncovering brain networks that could guide future treatments for opioid use disorder. #brain #psychiatry General Psychiatry https://lnkd.in/gp82bBjw
1
-
JAMA Pediatrics
This Viewpoint introduces the 4P's Road Map for translational population health and health equity research—moving from building blocks to innovations (interventions, therapies, policies, connections, etc) at scale, and toward optimal, equitable outcomes. https://ja.ma/4djJB2S
1
-
Lonely Therapy
Ultimately, a better understanding of the specific mechanisms underlying the effects of psychedelics could allow for a more targeted therapeutic approach. We highlight current challenges for psychedelic research and provide a research agenda to foster insight in the causal-mechanistic pathways underlying the efficacy of psychedelic research and therapy#Mindfulness https://lnkd.in/grXv6hFt
1
-
Market Access Today
🌟 Revolutionary Breakthrough in Cognitive Health! 🌟 A recent study by the MarkVCID consortium has validated the ARTS biomarker, showcasing its remarkable ability to predict cognitive decline in older adults linked to small vessel disease. 🧠✨ This fully automated software leverages MRI data and demographic insights to identify arteriolosclerosis, a crucial factor in vascular contributions to cognitive impairment and dementia (VCID). 🔍 Key Highlights: - Near-perfect inter-rater reliability (ICC of 0.9999) - Excellent test-retest repeatability (ICC=0.996) - Strong inter-scanner reproducibility (ICC=0.955) Clinical trials involving over a thousand non-demented older adults reveal that higher ARTS scores correlate with faster declines in cognitive performance, paving the way for early detection and intervention strategies. As dementia rates continue to rise globally, innovations like ARTS are vital for enhancing diagnostic precision and improving patient outcomes. 👉 Click the link for more insights into this groundbreaking development! #ARTSBiomarker #CognitiveHealth #DementiaResearch #HealthcareInnovation #NeurodegenerativeDiseases #Publications #RegulatoryAgencies #MarketAccess #MarketAccessToday
2
-
a-tune software
Scientists from Rockefeller University and Mount Sinai have unveiled a groundbreaking discovery shedding light on addiction. Their findings reveal a newly identified brain pathway that offers crucial insights into the neural processing of rewards and addictive substances. By delving into the nucleus accumbens (NAc), a key region involved in reward processing, the researchers discovered how cocaine and morphine activate specific subsets of neurons, leading to distinct behavioral outcomes compared to natural rewards. Moreover, they identified a molecular pathway involving the Rheb gene and the mTOR pathway, which may explain how addictive substances skew natural urges, such as hunger and thirst, by altering neural communication and memory. This research not only deepens our understanding of addiction but also opens new avenues for developing targeted interventions to restore the brain's natural reward processing mechanisms. Learn more: https://lnkd.in/esC6rVna #AddictionResearch #AnimalResearch #LaboratoryAnimalSciences
17
-
UC Davis Institute for Psychedelics and Neurotherapeutics
A recent study published in #Neuropharmacology with long-time IPN collaborator Jamie Peters, PhD, MBA explores how the psychedelic drug DOI can reduce motivation for heroin in a model involving both heroin and alcohol use. The study found that DOI, acting on 5-HT2A receptors, selectively decreases heroin motivation without affecting alcohol use. This research adds to the growing body of evidence supporting #psychedelics as promising treatments for substance use disorders! #SubstanceUseDisorder #OpioidCrisis
23
-
NEAD Centre
Individuals with bipolar disorder show considerable variability within clinical trajectories, cognitive status, and daily functioning, which challenges diagnostics and optimal treatment. However, the neurobiological markers underlying this phenotypic heterogeneity remain unclear. In a newly published article, we examine multivariate patterns between structural and functional neuroimaging and clinical, cognitive, and daily functioning variables in individuals with bipolar disorder. Key highlights: 🔍 We found a strong association among the imaging and behavioral data sets. Cognitive performance across tests of psychomotor speed, verbal memory, and verbal fluency were most strongly associated with multimodal imaging features in bipolar disorder, also when other clinical and functioning variables were considered. 🔍 In particular, aberrant hypo-activation within the dorsolateral prefrontal cortex and parietal regions during a working memory task were associated with poorer cognitive performance on tests of psychomotor speed, working memory, and executive functioning. Moreover, thinner temporal cortices were associated with poorer psychomotor speed, verbal memory, and working memory performance. 🔍 Our findings highlight the relationship between cognitive performance and multimodal imaging features in bipolar disorder. In particular, task activation within cognitive control areas, including the dorsal prefrontal cortex, may serve as neurocircuitry treatment targets for pro-cognitive interventions in bipolar disorder. Access the full article, published in Neuropsychopharmacology, here: https://lnkd.in/dsFTiRCx #Bipolardisorder #cognition #neuroimaging
30
-
Chris Aiken, MD
Accelerated iTBS is a rapid-acting TMS that stacks 10 sessions/day over a week. It has powerful effects for treatment resistant #depression (FDA approved as SAINT). Here is its first sham-controlled trial in treatment-resistant #bipolar depression: https://lnkd.in/evCqAusf Benefits were large, but trial was small (24)
295
22 Comments -
The Johns Hopkins University Applied Physics Laboratory
A persistent challenge in psychiatry is the lack of objective measures for evaluating and tracking mental health over time. https://jhuapl.link/kb9 By harnessing recent technological breakthroughs in physiological monitoring and machine learning, researchers at Johns Hopkins APL in collaboration with psychiatrists at Johns Hopkins Medicine, have made significant strides toward creating objective digital measures for assessing and tracking mental health. Tagged TEAPOT by its APL developers, the project encompasses a telehealth suite for performing “digital phenotyping” for psychiatric health to provide physicians with clinically relevant data during virtual visits. While traditional phenotyping entails deriving a person’s physical appearance from their DNA, digital phenotyping taps physiological data to estimate symptoms associated with psychiatric disorders, such as depression, anxiety and post-traumatic stress disorder. #JHUAPL | #JHU | Johns Hopkins Bloomberg School of Public Health | #psychiatry | #DigitalPhenotyping | #telehealth | #MentalHealth | #neurodiversity
25
-
International Brain Research Organization (IBRO)
Recent research published in #Neuroscience is attempting to slow down the progression of neurodegenerative diseases by stopping neural degeneration spreading from one neuron to the next. Learn more in the author interview with Gabriella Parrilla. 👉 https://lnkd.in/eY6qvMCt
23
-
University of Minnesota Department of Psychiatry & Behavioral Sciences
📚 *PUBLICATIONS ALERT* 📖 *Drs. Ziad Nahas and Kelvin Lim are coauthors of this study on Real-time TMS-EEG for brain state-controlled research and precision treatment: a narrative review and guide* https://lnkd.in/gDFkuCXe *Dr. Karina Quevedo is a coauthor of this study on Investigating Functional Connectivity in Adolescent Depression and Suicide Attempt during Neurofeedback Sessions: A Multivariate Random Covariance Model Approach* https://lnkd.in/gCGeAekw *Dr. Dorothy Hatsukami is a coauthor of this study on Leveraging information from secondary endpoints to enhance dynamic borrowing across subpopulations* https://lnkd.in/gHzpbEPj *Dr. Brenden Tervo-Clemmens is a coauthor of this study on the Neurobiology of attention-deficit hyperactivity disorder: historical challenges and emerging frontiers* https://lnkd.in/ggc34RAS *Dr. Sophia Vinogradov is a coauthor of this study on Oxygen Consumption In Vivo by Ultra-High Dose Rate Electron Irradiation Depends upon Baseline Tissue Oxygenation* https://lnkd.in/gYunrEGJ
10
-
AI Entrepreneurs
AI Cracks Cancer Code: New Tool Analyzes Biopsy Slides Researchers at Emory University and MD Anderson have developed METI (Morphology-Enhanced Spatial Transcriptome Analysis Integrator), a cutting-edge software tool that advances cancer pathology by integrating cellular morphology with gene expression data from biopsy samples. This innovative platform enhances the accuracy of cancer diagnosis by identifying both cancerous and non-cancerous cells, including immune cells, within the tumor microenvironment. Key Features: 1. Integrates spatial transcriptomics with cell morphology for precise tumor analysis. 2. Identifies various cell types, including immune cells, in biopsy samples. 3. Applicable across multiple cancer types (e.g., lung, bladder, gastric cancers). 4. Unsupervised method incorporating domain knowledge for robust performance. 5. User-friendly interface available on GitHub for easy data visualization. How It Works: METI utilizes advanced machine learning to combine histological features with gene expression data, enabling a detailed analysis of the tumor microenvironment. This integration allows for the stratification of cell types and states, improving the accuracy of cancer diagnosis and treatment planning. Stay ahead with the latest insights and breakthroughs in AI-driven healthcare. Subscribe now for free to read our upcoming newsletter- https://lnkd.in/drMdAFND #hearthealth #aihealthcare #healthcare #ainews #aiinmedicine #heartdisease #aibreakthroughs #aiinnovation #aidevelopments #cancercare #cancer #diabetes #breastcancer
-
AI Entrepreneurs
AI Cracks Cancer Code: New Tool Analyzes Biopsy Slides Researchers at Emory University and MD Anderson have developed METI (Morphology-Enhanced Spatial Transcriptome Analysis Integrator), a cutting-edge software tool that advances cancer pathology by integrating cellular morphology with gene expression data from biopsy samples. This innovative platform enhances the accuracy of cancer diagnosis by identifying both cancerous and non-cancerous cells, including immune cells, within the tumor microenvironment. Key Features: 1. Integrates spatial transcriptomics with cell morphology for precise tumor analysis. 2. Identifies various cell types, including immune cells, in biopsy samples. 3. Applicable across multiple cancer types (e.g., lung, bladder, gastric cancers). 4. Unsupervised method incorporating domain knowledge for robust performance. 5. User-friendly interface available on GitHub for easy data visualization. How It Works: METI utilizes advanced machine learning to combine histological features with gene expression data, enabling a detailed analysis of the tumor microenvironment. This integration allows for the stratification of cell types and states, improving the accuracy of cancer diagnosis and treatment planning. Stay ahead with the latest insights and breakthroughs in AI-driven healthcare. Subscribe now for free to read our upcoming newsletter- https://lnkd.in/drMdAFND #hearthealth #aihealthcare #healthcare #ainews #aiinmedicine #heartdisease #aibreakthroughs #aiinnovation #aidevelopments #cancercare #cancer #diabetes #breastcancer
-
AI Entrepreneurs
AI Cracks Cancer Code: New Tool Analyzes Biopsy Slides Researchers at Emory University and MD Anderson have developed METI (Morphology-Enhanced Spatial Transcriptome Analysis Integrator), a cutting-edge software tool that advances cancer pathology by integrating cellular morphology with gene expression data from biopsy samples. This innovative platform enhances the accuracy of cancer diagnosis by identifying both cancerous and non-cancerous cells, including immune cells, within the tumor microenvironment. Key Features: 1. Integrates spatial transcriptomics with cell morphology for precise tumor analysis. 2. Identifies various cell types, including immune cells, in biopsy samples. 3. Applicable across multiple cancer types (e.g., lung, bladder, gastric cancers). 4. Unsupervised method incorporating domain knowledge for robust performance. 5. User-friendly interface available on GitHub for easy data visualization. How It Works: METI utilizes advanced machine learning to combine histological features with gene expression data, enabling a detailed analysis of the tumor microenvironment. This integration allows for the stratification of cell types and states, improving the accuracy of cancer diagnosis and treatment planning. Stay ahead with the latest insights and breakthroughs in AI-driven healthcare. Subscribe now for free to read our upcoming newsletter- https://lnkd.in/drMdAFND #hearthealth #aihealthcare #healthcare #ainews #aiinmedicine #heartdisease #aibreakthroughs #aiinnovation #aidevelopments #cancercare #cancer #diabetes #breastcancer #biopsy
-
Entia
💡#AI could be the answer to positive patient outcomes💡 Fascinating research from Stanford Department of Medicine has developed an AI-powered program that can predict the activity of genes within tumours, based on routinely collected biopsy images. Determining what genomic changes are driving tumour growth to determine the best course of treatment can be time-consuming and slow, so using AI in this way could be a real game-changer. “This kind of software could be used to quickly identify gene signatures in patients’ tumours, speeding up clinical decision-making and saving the healthcare system thousands,” said Olivier Gevaert, PhD, an associate professor of biomedical informatics research and the paper's senior author. Tailored treatments to maximise effectiveness are proving hugely impactful; however, it is not the only form of personalised care available. Increasingly available data from remote patient monitoring is also allowing for more personalised decisions to be made in response to treatment tolerance. If you’d like to find out more about our at-home blood monitoring device, #Liberty, and how it can enhance patient care and improve patient outcomes, send us a message 👇🏽 https://lnkd.in/eWr42WMA #CancerCare #HealthcareInnovation #DigitalHealth #RemotePatientMonitoring #NHS #HospitalAtHome #AI #MedTech
23
-
Dr E. Shyam P. Reddy
New Pain Pathway Discovery Could Revolutionize Chronic Pain Treatment: Cellular research indicates that neuropilin-1 plays a crucial role in pain signaling, presenting a potential pathway for developing or repurposing treatments to manage chronic pain. Researchers at the NYU Pain Research Center have identified a novel receptor for nerve growth factor (NGF) that plays a critical role in pain signaling, despite being unable to signal independently. These findings, published in the Journal of Clinical Investigation, could pave the way for new treatments for arthritis, inflammatory pain, and cancer pain—addressing the limitations of previous therapies that failed in clinical trials due to side effects. “Nerve growth factor is unusual because it’s one of the few patient-validated targets for pain,” said Nigel Bunnett, professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry and the study’s senior author. “We wanted to think of a way of circumventing side effects in an effort to find safer, non-opioid therapies for arthritis and other forms of chronic pain.” NGF is a protein that promotes the growth and survival of neurons while also acting as a potent pain mediator in both animals and humans. It is released by cells in injured or diseased tissues and triggers pain by binding to its primary receptor, tropomyosin receptor kinase A (TrkA). To determine this, they observed that nerve growth factor has a stretch of amino acids that is known to allow other proteins to bind to NPR1. NRP1 was also expressed in the same cells at the nerve growth factor receptor TrkA. Examining pain-sensing neurons, the researchers found that NRP1 could bind to nerve growth factor with high affinity, and when NRP1 was blocked in neurons from both mice and humans, it inhibited nerve growth factor from signaling pain. The researchers concluded that NRP1 is a co-receptor for nerve growth factor, as—unlike TrkA—NRP1 is not known to signal on its Blocking NRP1 with established compounds is one option, as NRP1 inhibitors—including monoclonal antibodies—have already been developed to treat cancer. “We could test these monoclonal antibodies that target NRP1 in models of pain,” said Bunnett. “Because these treatments would target receptors at the surface of pain-sensing neurons, this specificity might avoid the side effects seen with other monoclonal antibodies that sequester all nerve growth factor in the body.” The researchers are also harnessing their new understanding of the pain signaling complex, determining the sites at which nerve growth factor, TrkA, and NRP1 interact, and generating peptides that disrupt them. In the Journal of Clinical Investigation study, the researchers created one such peptide that blocked the ability of nerve growth factor to interact with NRP1, which stopped pain in cellular studies.
11
-
Market Access Today
📊 Smart EMA Completion Rates Lag in Cognitively Impaired Groups 🧠 The rise of smartphone-based Ecological Momentary Assessment (smart EMA) offers real-time insights into health conditions, but how effective is it for those with cognitive impairments? A systematic review has revealed that while the overall completion rate for EMA protocols stands at 74.4%, individuals with cognitive challenges face significantly lower engagement levels. Key findings indicate: 🔍 Cognitive difficulties hinder consistent participation 🔍 Complex protocols may be less accessible 🔍 Lack of tailored support contributes to higher dropout rates This highlights the urgent need for enhanced protocol designs that accommodate cognitive limitations and simplify interactions. As we strive to improve health outcomes, establishing robust methodological frameworks is essential! 👉 Click the link to explore more about this vital research and its implications! #CognitiveHealth #DataCollection #HealthTech #MedTech #Publications #RegulatoryAgencies #ResearchInsights #SmartEMA #MarketAccess #MarketAccessToday
1
-
PCSS-MAUD
Want to learn more about the needs and treatment options for American Indian and Alaska Native (AI/AN) individuals with alcohol use disorder? Watch this webinar by Dr. Anthony Dekker on pcss-maud.org to explore multidisciplinary approaches to addressing AUD and SUD among AI/AN patients! #alcohol #americanindian #alaskanative #substanceuse
1
-
NanoDx, Inc.
🧠✨ Exciting new research from Massachusetts General Hospital reveals that low-level light therapy (LLLT) could significantly enhance brain healing for traumatic brain injury (TBI) patients. 🔎 Here are the key takeaways: 1️⃣ Innovative Treatment: The therapy uses a near-infrared light-emitting helmet that stimulates brain healing processes. 2️⃣ Rapid Improvement: Significant increases in brain connectivity were observed within two weeks of starting treatment, suggesting fast-acting benefits. 3️⃣ Wide Applicability: Beyond TBI, this non-invasive therapy could also benefit patients with PTSD, depression, and autism, indicating its broad therapeutic potential. 4️⃣ Mechanism: The light therapy works by enhancing cerebral blood flow, increasing mitochondrial function, and reducing oxidative stress, all of which contribute to neural repair and improved cognitive function. 5️⃣ Ongoing Research: While the short-term results are promising, ongoing studies aim to understand the long-term effects and optimal treatment protocols. This breakthrough represents a significant advancement in non-invasive treatments for brain injuries and neurological disorders. As research continues, let’s hope for more refined applications and broader adoption of this therapy, offering hope to millions affected by these conditions. Discover more about this breakthrough here: https://lnkd.in/enFHYKP6 #Healthcare #MedicalResearch #TraumaticBrainInjury #Neuroscience #HealthTech #HealthcareInnovation #BrainInjury
9
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More